Online inquiry

IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ303MR)

This product GTTS-WQ303MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IGF1R gene. The antibody can be applied in Colon sarcoma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000875.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3480
UniProt ID P08069
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IGF1R, 19D12(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ303MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2948MR IVTScrip™ mRNA-Anti-PDCD1, ANB-011(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ANB-011
GTTS-WQ11943MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA MLTA3698A
GTTS-WQ15912MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA XOMA 052
GTTS-WQ9845MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JTX-2011
GTTS-WQ13718MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RC48-0
GTTS-WQ6024MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ15684MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ10197MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LDP-02
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW